Command Palette

Search for a command to run...

Clinical Trials · NCT03043807

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment
26
Start date
Feb 2017
Locations
2 sites, United States
Primary endpoint
Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate
View Gonadorelin compound reference